ArticleImmuno-oncology technology2026

Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care.

E Bengala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.